2017 iBIO IndEx Breakout Sessions
iBIO IndEx 2017 is a place to converge and connect with key thought leaders and peers from diverse backgrounds, and emerge with new insight to help drive industry-wide growth and transformation. Our signature event is a forum to discuss the latest trends and innovations impacting our community. The IndEx breakout sessions feature esteemed speakers and panelists discussing crucial innovations across our diverse spectrum.
Don’t miss these breakout sessions and check out the full agenda and register at http://index.ibio.org
Breakout Session Details
The impact of end-to-end evidence management across the life sciences organization (9:00 am)
The health care ecosystem is in a period of unprecedented change, which has major implications for the way life sciences companies develop and commercialize products. The combination of value-based reimbursement and precision medicine is directing treatment toward personalized care—and requiring a reorientation around insights, ecosystems and resultant outcomes.
To thrive in this rapidly evolving environment, companies may need to embrace new operating models based on end-to-end (E2E) evidence management across the entire product life cycle. An E2E strategy can assist organizations in becoming more insights-driven, breaking down traditional siloes to enable the sharing of data and insights across the organization to inform critical decisions from R&D through commercialization
Presenters will discuss their perspective on an E2E strategy and how it can help identify new innovations, accelerate product development, support market access and commercialization.
David Flowers, Managing Director, Life Sciences Industry, Deloitte Services LP
Tony Hebden, Vice President of Health Economics and Outcomes Research, Abbvie. Walt Johnston, Senior Vice President, Sales & Marketing, Urology and Hospital,
Astellas Pharma US, Inc.
Jeff Morgan, Specialist Leader, Deloitte Consulting LLP
Do You Really Know What’s Happening in Your Therapeutic Areas? 2016 Royalty Rate and Deal Terms Survey (9:00 am)
Many sources of information on biopharmaceutical royalty rates and deal terms rely on either Freedom of Information (FOI) sources from public companies in the United States, which only represent “material” deals that are generally more than five years old, or rely on press releases or public announcements which are often positioned for maximum publicity or promotional impact (i.e., the hyperbole of “BIO Bucks”).
The Life Sciences Sectors of LES (U.S.A. and Canada) & LESI have partnered toconduct a landmark GLOBAL survey of royalty rates and deal terms for recent deals conducted in the past two years. The results represent significant information on early stage deals from universities, private biotech companies and deals submitted by international companies outside the USA and Canada.
This landmark global survey is unique for the biopharmaceutical industry. The results presented in this session will be highlights of the Survey Report to be published in February 2017. The findings provide insights certain to raise questions or challenge conventional thinking, especially for contemporary deals in recent and turbulent years.
Ben Bonifant, Partner, Triangle Insights Group, LLC
The Latest from Washington: How the Policy Agenda will Impact Biotech (2:30 pm)
Almost 100 days into office we now have a better idea about the policies the administration plans to pursue. This session will explore the current and likely issues that will impact the biotech community.
This session will provide a deeper dive on some of the issues that will be discussed during the two plenary sessions. Don’t miss this DC insiders perspective on what the industry needs to watch out for.
Amy Jensen Cunniffe is a Principal at EY’s Washington Council where she is a leader in the group with a focus on health care. In addition to her strong policy background in health, Cunniffe has also provided legislative and regulatory council on tax, labor, Social Security, and general business issues in both the private and public sectors.
Diversity in Clinical Trials and the Importance of Engagement with Underrepresented Communities (4:00 pm)
There is an urgent and unmet need to make clinical research and trials more accessible to underrepresented communities and individuals. This need is supported by the 2016 FDA mandate to ensure that research and participants are representative of the U.S. population. Accessibility will improve by facilitating engagement, programs and educational resources that reflect the communities of interest. Utilizing its diverse and representative advisory committee, PACT has launched an effort to increase participation by providing educational resources and engagement opportunities on clinical research that will reduce the stigma of participation in clinical trials. We feel that these efforts will impact previously held negative perceptions of research participation and build the trust and transparency required and thus enable individuals to think differently and participate more fully in the outcomes of their health.
Experts from industry, academia and patient organizations will help the audience understand the importance of this topic, current best practices and future directions.
Regina Greer Smith, MPH, LFACHE – Healthcare Research Associates LLC. Founder/Owner The S.T.A.R. Initiative A Research Engagement Program
Dr. Neelum Aggarwal, Population health neurologist and clinical researcher – Rush University Medical Center. Chief diversity officer – American Medical Women’s Association.
Dr. Paris Davis, Project Lead – Pastors 4 PCOR: Engaging Faith Based Communities.
Dr. Chris Reddick, Vice President, R&D Medical Professional Affairs, Takeda Pharmaceuticals